Microglia-inhibiting activity of Parkinson's disease drug amantadine

Neurobiology of Aging

Volumn 33, Issue 9, 2012, Pages 2145-2159

  Kim, Jong Heon ^a   Lee, Ho Won ^a   Hwang, Jaegyu ^a   Kim, Jaehong ^a   Lee, Min Jeong ^a   Han, Hyung Soo ^a   Lee, Won Ha ^b   Suk, Kyoungho ^a  

^a Kyungpook National University School of Medicine   (South Korea)

^b Kyungpook National University   (South Korea)

Author keywords

Amantadine; Microglia; Neuroinflammation; Parkinson's disease

Indexed keywords

AMANTADINE; BACTERIUM LIPOPOLYSACCHARIDE; NITRIC OXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; MALE; MEDIATOR RELEASE; MICROGLIA; MOUSE; NERVE CELL CULTURE; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

AMANTADINE; ANALYSIS OF VARIANCE; ANIMALS; ANTIPARKINSON AGENTS; CALCIUM-BINDING PROTEINS; CELL LINE; CELL SURVIVAL; COCULTURE TECHNIQUES; CYTOKINES; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; ENCEPHALITIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; LIPOPOLYSACCHARIDES; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICROFILAMENT PROTEINS; MICROGLIA; MPTP POISONING; NEURONS; NF-KAPPA B; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRITES; RATS; RNA, MESSENGER; SIGNAL TRANSDUCTION; TIME FACTORS; TYROSINE 3-MONOOXYGENASE;

EID: 84863483641     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2011.08.011     Document Type: Article

References (64)

1. Abdel-Salam O.M. Drugs used to treat Parkinson's disease, present status and future directions. CNS Neurol. Disord. Drug Targets 2008, 7:321-342.
2. Arif M., Chikuma T., Ahmed M.M., Nakazato M., Smith M.A., Kato T. Effects of memantine on soluble Alphabeta(25-35)-induced changes in peptidergic and glial cells in Alzheimer's disease model rat brain regions. Neuroscience 2009, 164:1199-1209.
3. Beigel J., Bray M. Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res 2008, 78:91-102.
4. Betakova T. M2 protein-a proton channel of influenza A virus. Curr. Pharm. Des 2007, 13:3231-3235.
5. Blanpied T.A., Clarke R.J., Johnson J.W. Amantadine inhibits NMDA receptors by accelerating channel closure during channel block. J. Neurosci 2005, 25:3312-3322.
6. Block M.L., Zecca L., Hong J.S. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat. Rev. Neurosci 2007, 8:57-69.
7. Bocchini V., Mazzolla R., Barluzzi R., Blasi E., Sick P., Kettenmann H. An immortalized cell line expresses properties of activated microglial cells. J. Neurosci. Res 1992, 31:616-621.
8. Cady S.D., Schmidt-Rohr K., Wang J., Soto C.S., Degrado W.F., Hong M. Structure of the amantadine binding site of influenza M2 proton channels in lipid bilayers. Nature 2010, 463:689-692.
9. Cheepsunthorn P., Radov L., Menzies S., Reid J., Connor J.R. Characterization of a novel brain-derived microglial cell line isolated from neonatal rat brain. Glia 2001, 35:53-62.
10. Chen J.J., Swope D.M. Pharmacotherapy for Parkinson's disease. Pharmacotherapy 2007, 27:161S-173S.
11. Cunningham C., Wilcockson D.C., Campion S., Lunnon K., Perry V.H. Central and systemic endotoxin challenges exacerbate the local inflammatory response and increase neuronal death during chronic neurodegeneration. J. Neurosci 2005, 25:9275-9284.
12. Davies W.L., Grunert R.R., Haff R.F., McGahen J.W., Neumayer E.M., Paulshock M., Watts J.C., Wood T.R., Hermann E.C., Hoffmann C.E. Antiviral activity of 1-adamantanamine (Amantadine). Science 1964, 144:862-863.
13. de Roin S., Winters S. Amantadine hydrochloride: current and new uses. J. Neurosci. Nurs 1990, 22:322-325.
14. Diaz N.L., Waters C.H. Current strategies in the treatment of Parkinson's disease and a personalized approach to management. Expert Rev. Neurother 2009, 9:1781-1789.
15. Gao H.M., Liu B., Zhang W., Hong J.S. Novel anti-inflammatory therapy for Parkinson's disease. Trends Pharmacol. Sci 2003, 24:395-401.
16. Godwin-Austen R.B., Frears C.C., Bergmann S., Parkes J.D., Knill-Jones R.P. Combined treatment of parkinsonism with L-dopa and amantadine. Lancet 1970, 2:383-385.
17. Grunert R.R., McGahen J.W., Davies W.L. The in vivo antiviral activity of 1-adamantanamine (Amantadine). I. Prophylactic and therapeutic activity against influenza viruses. Virology 1965, 26:262-269.
18. Hwang J., Hwang H., Lee H.W., Suk K. Microglia signaling as a target of donepezil. Neuropharmacology 2010, 58:1122-1129.
19. Hwang J., Zheng L.T., Ock J., Lee M.G., Kim S.H., Lee H.W., Lee W.H., Park H.C., Suk K. Inhibition of glial inflammatory activation and neurotoxicity by tricyclic antidepressants. Neuropharmacology 2008, 55:826-834.
20. Imai Y., Ibata I., Ito D., Ohsawa K., Kohsaka S. A novel gene iba1 in the major histocompatibility complex class III region encoding an EF hand protein expressed in a monocytic lineage. Biochem. Biophys. Res. Commun 1996, 224:855-862.
21. Kim W.G., Mohney R.P., Wilson B., Jeohn G.H., Liu B., Hong J.S. Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J. Neurosci 2000, 20:6309-6316.
22. Kim Y.S., Joh T.H. Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson's disease. Exp. Mol. Med 2006, 38:333-347.
23. Kubera M., Basta-Kaim A., Budziszewska B., Rogóz Z., Skuza G., Leskiewicz M., Tetich M., Jaworska-Feil L., Maes M., Lason W. Effect of amantadine and imipramine on immunological parameters of rats subjected to a forced swimming test. Int. J. Neuropsychopharmacol 2006, 9:297-305.
24. Kunz A., Abe T., Hochrainer K., Shimamura M., Anrather J., Racchumi G., Zhou P., Iadecola C. Nuclear factor-kappaB activation and postischemic inflammation are suppressed in CD36-null mice after middle cerebral artery occlusion. J. Neurosci 2008, 28:1649-1658.
25. Lawson L.J., Perry V.H., Dri P., Gordon S. Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 1990, 39:151-170.
26. Lee H., Kim Y.O., Kim H., Kim S.Y., Noh H.S., Kang S.S., Cho G.J., Choi W.S., Suk K. Flavonoid wogonin from medicinal herb is neuroprotective by inhibiting inflammatory activation of microglia. FASEB J 2003, 17:1943-1944.
27. Lee S., Park J.Y., Lee W.H., Kim H., Park H.C., Mori K., Suk K. Lipocalin-2 is an autocrine mediator of reactive astrocytosis. J. Neurosci 2009, 29:234-249.
28. Lee S.J., Lee S. Toll-like receptors and inflammation in the CNS. Curr. Drug Targets. Inflamm. Allergy 2002, 1:181-191.
29. Lehnardt S., Massillon L., Follett P., Jensen F.E., Ratan R., Rosenberg P.A., Volpe J.J., Vartanian T. Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:8514-8519.
30. Liu B., Yang R., Wong K.A., Getman C., Stein N., Teitell M.A., Cheng G., Wu H., Shuai K. Negative regulation of NF-kappaB signaling by PIAS1. Mol. Cell. Biol 2005, 25:1113-1123.
31. Liu M., Bing G. Lipopolysaccharide animal models for Parkinson's disease. Parkinsons Dis 2011, 2011:327089.
32. Long-Smith C.M., Sullivan A.M., Nolan Y.M. The influence of microglia on the pathogenesis of Parkinson's disease. Prog. Neurobiol 2009, 89:277-287.
33. McCarthy K.D., de Vellis J. Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. J. Cell Biol 1980, 85:890-902.
34. McClelland R.A., Finlay P., Walker K.J., Nicholson D., Robertson J.F., Blamey R.W., Nicholson R.I. Automated quantitation of immunocytochemically localized estrogen receptors in human breast cancer. Cancer Res 1990, 50:3545-3550.
35. McGeer E.G., McGeer P.L. The role of anti-inflammatory agents in Parkinson's disease. CNS Drugs 2007, 21:789-797.
36. McGeer P.L., McGeer E.G. Glial reactions in Parkinson's disease. Mov. Disord 2008, 23:474-483.
37. McLean P.J., Kawamata H., Hyman B.T. Alpha-synuclein-enhanced green fluorescent protein fusion proteins form proteasome sensitive inclusions in primary neurons. Neuroscience 2001, 104:901-912.
38. McMillian M., Kong L.Y., Sawin S.M., Wilson B., Das K., Hudson P., Hong J.S., Bing G. Selective killing of cholinergic neurons by microglial activation in basal forebrain mixed neuronal/glial cultures. Biochem. Biophys. Res. Commun 1995, 215:572-577.
39. Morgan M.J., Liu Z.G. Crosstalk of reactive oxygen species and NF-κB signaling. Cell Res 2011, 21:103-115.
40. Ock J., Han H.S., Hong S.H., Lee S.Y., Han Y.M., Kwon B.M., Suk K. Obovatol attenuates microglia-mediated neuroinflammation by modulating redox regulation. Br. J. Pharmacol 2010, 159:1646-1662.
41. Ohsawa K., Imai Y., Kanazawa H., Sasaki Y., Kohsaka S. Involvement of Iba1 in membrane ruffling and phagocytosis of macrophages/microglia. J. Cell Sci 2000, 113:3073-3084.
42. Ossola B., Schendzielorz N., Chen S.H., Bird G.S., Tuominen R.K., Männistö P.T., Hong J.S. Amantadine protects dopamine neurons by a dual action: Reducing activation of microglia and inducing expression of GNDF in astroglia. Neuropharmacology 2011, 61:574-582.
43. Pierri M., Vaudano E., Sager T., Englund U. KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse. Neuropharmacology 2005, 48:517-524.
44. Qin L., Wu X., Block M.L., Liu Y., Breese G.R., Hong J.S., Knapp D.J., Crews F.T. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 2007, 55:453-462.
45. Roman A., Rogóz Z., Kubera M., Nawrat D., Nalepa I. Concomitant administration of fluoxetine and amantadine modulates the activity of peritoneal macrophages of rats subjected to a forced swimming test. Pharmacol. Rep 2009, 61:1069-1077.
46. Rosi S., Ramirez-Amaya V., Vazdarjanova A., Esparza E.E., Larkin P.B., Fike J.R., Wenk G.L., Barnes C.A. Accuracy of hippocampal network activity is disrupted by neuroinflammation: rescue by memantine. Brain 2009, 132:2464-2477.
47. Rosi S., Vazdarjanova A., Ramirez-Amaya V., Worley P.F., Barnes C.A., Wenk G.L. Memantine protects against LPS-induced neuroinflammation, restores behaviorally-induced gene expression and spatial learning in the rat. Neuroscience 2006, 142:1303-1315.
48. Saniova B., Drobny M., Kneslova L., Minarik M. The outcome of patients with severe head injuries treated with amantadine sulphate. J. Neural Transm 2004, 111:511-514.
49. Saura J., Tusell J.M., Serratosa J. High-yield isolation of murine microglia by mild trypsinization. Glia 2003, 44:183-189.
50. Schreiber E., Matthias P., Müller M.M., Schaffner W. Rapid detection of octamer binding proteins with "mini-extracts", prepared from a small number of cells. Nucleic Acids Res 1989, 17:6419.
51. Schubert D., Heinemann S., Carlisle W., Tarikas H., Kimes B., Patrick J., Steinbach J.H., Culp W., Brandt B.L. Clonal cell lines from the rat central nervous system. Nature 1974, 249:224-227.
52. Schwab R.S., England A.C., Poskanzer D.C., Young R.R. Amantadine in the treatment of Parkinson's disease. JAMA 1969, 208:1168-1170.
53. Takeda K., Muramatsu M., Chikuma T., Kato T. Effect of memantine on the levels of neuropeptides and microglial cells in the brain regions of rats with neuropathic pain. J. Mol. Neurosci 2009, 39:380-390.
54. Tampi R.R., van Dyck C.H. Memantine: efficacy and safety in mild-to-severe Alzheimer's disease. Neuropsychiatr. Dis. Treat 2007, 3:245-258.
55. Thomas S.J., Grossberg G.T. Memantine: a review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias. Clin. Interv. Aging 2009, 4:367-377.
56. Toide K. Effects of amantadine on dopaminergic neurons in discrete regions of the rat brain. Pharmacol. Res 1990, 7:670-672.
57. Tufekci K.U., Genc S., Genc K. The endotoxin-induced neuroinflammation model of Parkinson's disease. Parkinsons Dis 2011, 2011:487450.
58. Vallabhapurapu S., Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu. Rev. Immunol 2009, 27:693-733.
59. Waak J., Weber S.S., Waldenmaier A., Görner K., Alunni-Fabbroni M., Schell H., Vogt-Weisenhorn D., Pham T.T., Reumers V., Baekelandt V., Wurst W., Kahle P.J. Regulation of astrocyte inflammatory responses by the Parkinson's disease-associated gene DJ-1. FASEB J 2009, 23:2478-2489.
60. Whitton P.S. Inflammation as a causative factor in the aetiology of Parkinson's disease. Br. J. Pharmacol 2007, 150:963-976.
61. Wilms H., Zecca L., Rosenstiel P., Sievers J., Deuschl G., Lucius R. Inflammation in Parkinson's diseases and other neurodegenerative diseases: cause and therapeutic implications. Curr. Pharm. Des 2007, 13:1925-1928.
62. Wu H.M., Tzeng N.S., Qian L., Wei S.J., Hu X., Chen S.H., Rawls S.M., Flood P., Hong J.S., Lu R.B. Novel neuroprotective mechanisms of memantine: increase in neurotrophic factor release from astroglia and anti-inflammation by preventing microglial activation. Neuropsychopharmacology 2009, 34:2344-2357.
63. Yahr M.D., Duvoisin R.C. Drug therapy of parkinsonism. N Engl J. Med 1972, 287:20-24.
64. Zheng L.T., Hwang J., Ock J., Lee M.G., Lee W.H., Suk K. The antipsychotic spiperone attenuates inflammatory response in cultured microglia via the reduction of proinflammatory cytokine expression and nitric oxide production. J. Neurochem 2008, 107:1225-1235.